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There are limited data about combining delamanid and bedaquiline in drug-resistant 
tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV-
infected persons, are unavailable.  
We prospectively followed up 122 South Africans (52.5% HIV-infected) with DR-TB and poor 
prognostic features between 2014 and 2018. We compared outcomes and safety in those who 
received a bedaquiline-based regimen (n=82) to those who received a bedaquiline-delamanid 
combination regimen (n=40). 
There was no significant difference in 6-month culture conversion (92.5% versus 81.8%; 
p=0.26) and 18-month favourable outcome rate (63.4% versus 67.5%; p=0.66) in the 
bedaquiline versus the bedaquiline-delamanid combination group, despite the latter having 
more advanced drug resistance (3.7% versus 22.5% resistant > 5 drugs; p= 0.001) and higher 
pre-treatment failure rates (12.2% versus 52.5% with pre-treatment MDR-TB therapy failure; 
p <0.001). Although the proportion of QTcF prolongation was higher in the combination group 
[>60 ms from baseline (p=0.001) or > 450 ms during treatment (p=0.001)], there were no 
symptomatic cases or drug withdrawal in either group. Results were similar in HIV-infected 
patients. 
A bedaquiline-delamanid combination regimen showed comparable long-term safety, to a 
bedaquiline-based regimen, in patients with DR-TB irrespective of HIV status. These data 
inform regimen selection in patients with DR-TB from TB endemic settings. 
  
Introduction 
Drug resistant tuberculosis (DR-TB) constitutes a threat to TB control globally. In 2017, and 
despite high rates of underreporting and underdiagnosis, there was a 5% increase in the absolute 
number of DR-TB cases detected compared to 2016[1, 2]. Treatment outcomes of MDR-TB 
have also remained poor with a treatment success rate of 55% reported in 2017 [3, 4]. However, 
this is expected to improve given that newer and repurposed drugs have now been 
recommended by the world health organisation (WHO) for the treatment of multidrug resistant 
TB (MDR-TB)[5]. Indeed, studies and regimens containing bedaquiline and linezolid have 
shown impressive efficacy in clinical trials and real-life programmatic use[6-10]. 
Nevertheless, even with the use of these newer drugs, successful outcomes and treatment 
options are limited in patients with fluoroquinolone-resistant and XDR-TB [7]. Thus, there is 
frequently a difficulty in constituting an effective treatment regimen [11-15]. Patients who have 
had previous exposure to second line TB medication, developed resistance to multiple drugs, 
developed intolerability due to adverse events [16], and those who have failed therapy on 
bedaquiline-based regimens, are all predisposed to having a poor prognosis. In this group of 
patients, it is challenging to constitute a treatment regimen containing at least 4 to 5 likely 
effective drugs (drugs to which the isolate was susceptible and/ or to which patients had less 
than one month or no previous exposure) without simultaneously including bedaquiline and 
delamanid. The latter, a group C drug, remains widely used in clinical practice although there 
is currently limited evidence about the efficacy of delamanid for the treatment of MDR-TB 
[17-19].  
Thus, in appropriate patients with high level resistance and/ or poor prognosis there is an 
increasing need to use a bedaquiline-delamanid combination. However, the potential for 
synergistic QTc prolongation from both drugs, predisposing patients to cardiac arrythmias and 
sudden death, has created unease over their inclusion in the same treatment regimen [4, 20-22]. 
Despite this concern and more widespread use, few studies have reported on the concurrent use 
of delamanid and bedaquiline and have mostly described early safety and efficacy of the 
combination in retrospective cohorts [23, 24]. There are, however, no prospective and long-
term data addressing safety, and none addressing efficacy of the combination regimen in 
patients with poor prognosis from a TB endemic setting. Furthermore, there are limited data 
about use of the bedaquiline-delamanid combination in HIV co-infected patients, and those 
with high level resistance e.g. patients with XDR-TB. Another major limitation has been the 
lack of comparative data from a bedaquiline only control group, so that the net effect of 
delamanid safety (and QT prolongation) over that of bedaquiline, could be ascertained. We 
therefore compared the treatment outcomes and adverse event profiles of DR-TB patients with 
poor prognostic features on a bedaquiline-based regimen to those who had received the 
bedaquiline-delamanid combination. 
Methods 
Study design and participants 
We prospectively recruited, through an ongoing clinical registry, microbiologically-confirmed 
MDR-TB patients who were admitted to Brooklyn Chest Hospital, the designated treatment 
centre for drug resistant TB in the Western Cape province in South Africa. However, a per 
protocol analysis plan was only formulated retrospectively. All patients were admitted between 
January 2014 and April 2018. Patients were included in the study if their drug susceptibility 
and testing done prior to recruitment showed resistance to at least rifampicin and isoniazid. 
Sputum drug susceptibility and testing was repeated on a monthly basis following treatment 
initiation, to monitor treatment progress. Each patient received either a bedaquiline-based or a 
bedaquiline-delamanid combination regimen. Medications were administered by trained health 
care workers while patients were on admission and on outpatient basis after discharged from 
the hospital.  
Adverse events were reported by a medically qualified health care worker, using a 
pharmacovigilance report form provided for each patient. Each patient had an 
electrocardiogram (ECG) done before treatment initiation and at least on a monthly basis 
afterwards. QT interval was corrected using Friderica’s formula (QTcF), and values greater 
than 450ms qualifies a patient for closer review by attending physician. Patients’ demographic 
and clinical data were captured by a trained researcher, laboratory reports were regularly 
updated on a dedicated database using a standard case report form. A written consent was 
obtained from every participant, and ethical clearance was obtained from the University of 
Cape Town Human Research Ethics Committee. 
Treatment groups 
All patients were assigned a treatment group based on the drugs that constitute the backbone 
of their regimen. Bedaquiline was the backbone in the bedaquiline-based regimen group while 
the second group received a regimen whose backbone was a combination of bedaquiline and 
delamanid (bedaquiline-delamanid), administered concurrently. Indications for receiving the 
combination therapy were inability to construct an effective regimen (at least 4 likely effective 
drugs) due to extensive drug resistance patterns or adverse events, strengthening of a regimen 
due to late conversion, or extensive lung disease and patients who have previously failed on a 
bedaquiline-based regimen. Medications were individualised for patients based on their 
phenotypic drug susceptibility testing results. 
Outcomes  
Culture conversion was defined as two consecutive negative sputum culture results, taken at 
least 30 days apart (one missing or contaminated culture was allowed between negative 
cultures, and inability to produce sputum was considered to be a negative result). Culture 
conversion status was compared between the two groups at two months, six months and twelve 
months following treatment initiation. In the first six months of therapy, changes in the QTcF 
interval from baseline values were also compared between the two groups to establish how it 
is impacted by the treatment regimens. At follow-up censor date which was a minimum of 18 
months, patients were assigned to have had a favourable outcome if they completed treatment 
or were cured, those who died during treatment, failed to achieve culture conversion or lost to 
follow-up were said to have had an unfavourable outcome. 
Statistical Analysis 
The impact of delamanid was determined by comparative analysis of demographics, clinical 
characteristics, and treatment outcomes. Qualitative and quantitative variables were reported 
in percentages and median (interquartile range; IQR). Quantitative and qualitative variables 
were compared using Mann-Whitney U and chi-square or Fisher’s exact tests respectively. A 
univariate Cox proportional hazard model was used to estimate the relationship between 
independent variables (demographic and clinical characteristics) and the development of 
unfavourable outcome and, having at least one QTc value of greater than 450 ms; variables 
with a p-value less than 0.3 were included in the multivariate model. A p-value of <0.05 was 
taken as statistically significant. Kaplan-Meier curves for the probability of achieving an 
unfavourable outcome and the proportion of patients with culture positivity were estimated 
considering the duration between the day of treatment initiation and follow-up censor date. 
Comparison between strata (bedaquiline-based therapy and bedaquiline-delamanid 
combination therapy) were undertaken using a log-rank test. Statistical analysis was done using 
IBM SPSS Statistics Version 25.0(IBM Corp., Armonk, NY, USA). 
 
Results 
Demographic and clinical characteristics 
In this study, a total of 122 culture-confirmed multidrug-resistant TB patients were enrolled 
into either a bedaquiline-based regimen group or a bedaquiline-delamanid combination 
regimen group. Median age at admission was 34 (IQR 27-42) years, they were on admission 
for a median 161 (IQR 102-230) days and 74 (60.7%) were male. The median weight at 
admission was 51.8 (IQR 43.8-59.0) kg, 64 (52.5%) patients were HIV-infected with median 
CD4 count of 154 (IQR 57- 332) cells/µl and they were all on antiretroviral therapy. Isolates 
from 11 (9%) patients were outrightly multidrug resistant (MDR-TB), 25 (20.5%) patients had 
further resistance to either a fluoroquinolone or a second line injectable (Pre-XDR TB), while 
86 (70.5%) patients were resistant to both (XDR-TB).  
There were 82 (67.2%) patients in the group who received bedaquiline-based regimen, they 
were hospitalised for a median 155 (IQR93-210) days. Patients demographic and clinical 
characteristics are outlined in Table 1. They received a median 8 (IQR 7-9) medications in the 
regimen which essentially comprised of bedaquiline, clofazimine, levofloxacin and linezolid 
as the major components. Other drugs and the proportion of patients who received them are 
outlined in Table 2. All patients received clofazimine or a fluoroquinolone which are known 
QTc prolonging drugs. 23 patients (28.1%) received both drugs, 55 patients (67.1%) received 
only clofazimine while 3 (3.7%) patients received only moxifloxacin in their regimen. 
In the bedaquiline-delamanid combination regimen group, 40 (32.8%) patients were enrolled 
and they were hospitalized for a median 204 (IQR 124-295) days. 29 (72.5%) patients have 
been previously treated for TB, 9 (22.5%) were resistant to at least five drugs; other markers 
of disease severity are highlighted in Table 1. They received a median 10 (IQR 8-11) 
medications in the regimen which was significantly more than medications received in the 
bedaquiline-based regimen. The major medications in this regimen are delamanid, bedaquiline, 
clofazimine, levofloxacin and linezolid. 37 (92.5%) patients in this group received at least one 
of clofazimine and moxifloxacin. 14 patients (35.0%) received both drugs, 21 patients (52.5%) 
received only clofazimine while 2 (5.0%) patients received only moxifloxacin in their regimen. 
Markers of disease severity 
There were significantly more patients (72.5%) in the bedaquiline-delamanid combination 
regimen group with previous exposure to TB treatment compared to those in the bedaquiline-
based regimen (48.8%; p=0.01).  More patients in the combination therapy group have 
previously failed TB treatment compared to those in the bedaquiline group (52.5% vs 12.2%; 
p<0001). The bedaquiline-delamanid combination regimen group also had significantly more 
patients with resistance to more than five drugs (22.5% vs 3.7%; p=0001). Other markers of 
disease severity including HIV-infection, microbial burden and weight less than 50 kg at 
admission were mostly higher in the bedaquiline-delamanid combination regimen group (Table 
1). 
Culture conversion 
In the bedaquiline-based regimen group, 52 patients (63.4%) were culture positive at 
recruitment, 92.5% of those with laboratory results had achieved culture conversion by six 
months of treatment. Of the 42 HIV-infected patients in this group, 23 (54.8) were culture 
positive at recruitment, and 93.8% of those with laboratory results have achieved culture 
conversion by six months of treatment.  
In the bedaquiline-delamanid combination regimen, 26 patients (65%) were culture positive at 
recruitment, 81.8% of those with laboratory results had achieved culture conversion by six 
months of treatment. Of the 22 HIV-infected patients in this group, 13 (59.1%) were culture 
positive at recruitment, 83.3% of those with laboratory results had achieved culture conversion 
by six months of treatment. Comparison of culture conversion rates in both groups are outlined 
in Table S1 (Online supplement). In time to event analysis, there were more patients in the 
bedaquiline-delamanid combination group with culture positivity compared to those in the 
bedaquiline group by the end of the fifteenth month (p=0.04; Figure 1). 
Efficacy of the treatment regimens 
In the bedaquiline-based regimen group, 52 patients (63.4%) achieved a favourable outcome 
while the remaining patients had unfavourable outcome by the end of follow-up period. 29 
(69.1%) out of 42 HIV-infected patients in this group also, achieved a favourable outcome. In 
the bedaquiline-delamanid combination regimen group, 27 patients (67.5%) achieved a 
favourable outcome while the remaining patients had unfavourable outcome by the end of 
follow-up period. 15 (68.2%) out of 22 HIV-infected patients in this group also, achieved a 
favourable outcome. There was no significant difference in the favourable outcome rate 
between the two groups even when they were stratified by resistance patterns (Table 1; online 
supplement Table S2). In time to event analysis, there was no difference in the probability of 
achieving an unfavourable outcome between the two groups (p=0.54; Figure 1). Regression 
analysis showed that moxifloxacin (HR 1.023; p=0.89) and clofazimine (HR 0.711; p=0.35) 
which were the other QTcF prolonging drugs used in both regimens did not predispose to 
having unfavourable outcome (Table 3). It also suggested that days to sputum culture positivity 
less than seven days (H.R.= 2.712; p=0.006) and resistance to more than five drugs (H.R.= 
2.173; p=0.08) are independent predictors of an unfavourable outcome (Table 3). 
Adverse events 
In the bedaquiline-based regimen group, 73 patients (89.0%) reported a total of 250 adverse 
events, each patient reporting a median 2 (IQR 1-4) adverse events in the course of treatment. 
The most commonly reported adverse events were hearing loss (50.0%), most likely from 
previous second line injectable treatment, elevated liver enzymes (28%) with median ALT of 
112 U/L (IQR 81-173) in affected patients, anaemia (34.1%), peripheral neuropathy (22.0%) 
and vomiting (24.4%). ALT elevation in the HIV-infected patients in this group was by a 
median 107 U/L (IQR 71-154). 
In the bedaquiline-delamanid combination regimen group, 37 patients (92.5%) reported a total 
of 125 adverse events, each patient reporting a median 3 (IQR 2-4) adverse events in the course 
of treatment. The most commonly reported adverse events in this group were hearing loss 
(45%), elevated liver enzymes (32.5%) with median ALT of 111U/L (IQR 85-155), anaemia 
(37.5%) and peripheral neuropathy (30.0%).  ALT elevation in the HIV-infected patients in 
this group was by a median 133 U/L (IQR 91-155), this was essentially similar to those in the 
bedaquiline regimen (p=0.34). There were no significant differences in the occurrence of 
adverse events reported in the two groups except for psychosis which was likely associated 
with higher rate of simultaneous use of terizidone and high dose isoniazid in the bedaquiline-
delamanid combination regimen group. Other adverse events and the proportion of patients 
who had them are reported in Table 4. 
 
 
QTcF interval changes 
The median baseline QTcF value for the bedaquiline-based regimen group was 408 ms (IQR 
388-425). In the first six months of treatment, there was a maximum QTcF prolongation of 
median 27 ms (IQR 13-42) from the baseline values, and only 6 patients (7.3%) had a QTcF 
prolongation greater than 60 ms from baseline values. 16 patients (19.5%) in this group also 
had at least one QTcF value greater than 450 ms in the course of treatment, but none reached 
the threshold limit of 500 ms, and none of them had bedaquiline discontinued due to changes 
in QTcF values (Table 5). 
The median baseline QTcF value for the bedaquiline-delamanid regimen group was 419 ms 
(389-436). In the first six months of treatment, there was a maximum QTcF prolongation of 
median 23 ms (8-54) from the baseline values, and only 7 patients (20.6%) had a QTcF 
prolongation greater than 60 ms from baseline values. 15 patients (44.1%) in this group also 
had at least one QTcF value greater than 450 ms in the course of treatment, none of them 
reached the threshold limit of 500 ms, and neither bedaquiline nor delamanid was discontinued 
in any of the patients due to changes in QTcF values (Table 5). 
There was no definitive pattern to the changes (increase or decrease) in QTcF values observe 
over a period of 6 months (online supplement Figure S1, but there were more patients in the 
bedaquiline-delamanid regimen group who reported a QTcF prolongation of more than 60 ms 
from baseline values (p<0.001) and at least one QTcF value greater than 450 ms (p<0.001) in 
the course of treatment.  Increasing age (H.R.=1.039; p= 0.04) and the use of delamanid (H.R.= 
3.504; p= 003) were independent predictors of having at least one QTcF value greater than 450 
ms (Table 6). There were however no cardiac symptoms necessitating the withdrawal of 





This is the first prospective study comparing long-term treatment outcomes and safety data in 
drug-resistant TB patients who received bedaquiline versus bedaquiline-delamanid 
combination therapy. The main findings of the study were that (i) combination therapy was 
associated with significant QTcF prolongation from baseline values but there were no patients 
who became symptomatic from a cardiovascular point of view (syncope, collapse, arrythmia, 
hypotension etc.) or reached the threshold limit of 500ms that would have necessitated 
recommended withdrawal of either bedaquiline or delamanid (and despite the concomitant use 
of other QT-prolonging drugs), (ii) bedaquiline-delamanid combination therapy was associated 
with modestly good culture conversion and favourable outcome rates (and comparable to a 
bedaquiline-based regimen) despite being used in patients from a poorer prognostic category 
i.e. high proportion of  patients who had previously been declared therapeutically destitute, 
and/ or whose isolates were resistant to > 5 drugs, and (iii) these findings were broadly similar 
in HIV-infected patients.  
 
Thus, our data support the use of the combination in patients in whom there is a difficulty in 
constituting a regimen with at least four effective drugs. Our data are concordant with 2 recent 
publications, which also confirmed the safety profile of the bedaquiline/delamanid 
combination[24, 25]. However, there are several important strengths and incremental 
contributions of our study findings. Here, we are able to confirm the long-term safety, safety 
in HIV-infected persons (which has always remained the concern given their higher frequency 
of adverse events to drugs in general), and importantly we were able to discern the incremental 
QT prolongation effect of delamanid within the combination, when compared to a bedaquiline 
only group. This should allay anxiety amongst clinicians who often need to include delamanid 
in treatment regimens but are concerned by the WHO Guidelines which express reservation 
about the safety of simultaneous use of these drugs[26]. Other QT-prolonging drugs like 
clofazimine and moxifloxacin were used substantially, and to a similar extent, in both groups 
and thus we could account for their effect when comparisons were made. Nevertheless, ECG 
monitoring is still required when the combination is used, especially together with other QT-
prolonging drugs, given that discontinuation of drugs have been documented in a few 
patients[26]. However, our findings support the notion that this is not a major issue and is 
uncommon. 
We were also able to evaluate the long-term efficacy, in terms of outcomes, in the bedaquiline 
only and combination groups, respectively. It is reassuring that we found similar long-term 
outcomes in the bedaquiline-delamanid combination group despite this group having a higher 
frequency of poor prognostic features (at least half the group were MDR treatment failures 
compared to ~10% in the bedaquiline group, and almost a quarter of isolates in the combination 
group were resistant to 5 or more drugs compared to about ~5% in the bedaquiline only group). 
Furthermore, usage of WHO group A and group B drugs, i.e. (linezolid, any fluoroquinolone, 
clofazimine, and terizidone) were similar in both groups. Despite recent findings suggesting 
limited efficacy of this drug (and when using 6-month culture conversion as an outcome)[17], 
our data suggest that delamanid may be a useful addition in patients where an appropriate 
regimen of 4 to 5 likely effective drugs cannot be constituted because of toxicity or high-level 
resistance. Indeed, despite the combination group having an ~50% prior treatment failure rate, 
the 6-month culture conversion rate in this group was over 80%, and the overall long-term 
favourable outcome rate was almost 70%. This far exceeds the dismal outcomes seen with 
XDR-TB prior to the advent of newer drugs[27, 28]. Nevertheless, ~10% of patients in each 
group failed treatment. Thus, programmatically incurable TB is an emerging problem in TB 
endemic countries and public health efforts are needed to manage such patients on a long-term 
basis. Besides establishing palliative care and long-term community-based residential 
facilities[29], preventative measures such as optimal antibiotic stewardship, active case 
finding, and wider roll-out of new diagnostics and drugs are urgently required[15]. 
In HIV-infected patients the adverse event profile and treatment outcomes showed similar 
patterns compared to HIV-uninfected patients. These findings are highly relevant to high TB 
and HIV-endemic settings. Besides QT-prolongation, other important adverse events, such as 
elevation of liver enzymes, were found to be similar in the HIV-infected patients in both 
groups, further confirming safety and compatibility with antiretrovirals in this group. 
There are several limitations of our findings. Our study was of limited sample size and a larger 
study may have shown different results given that cardiovascular events related to QT 
prolongation is rare. A larger sample size may have also allowed some clear-cut outcome effect 
to be discerned. However, this study has reported the largest number of patients on bedaquiline-
delamanid combination therapy (n = 40), the largest number of patients with XDR-TB (n = 
86), and the multivariable analysis, even when taking into account the poorer prognostic 
features in the combination group, failed to identify the combination as an independent 
predictor of outcome. Rather, bacterial load remained the only significant and independent 
predictor of outcome. This highlights another limitation, which is the failure to evaluate 
radiographic disease extent at the time of diagnosis, which would better enable us to account 
for initial disease severity. However, logistical and technical issues prevented us from 
accessing the pre-treatment chest radiographs. Nevertheless, we were able to get a fairly good 
comparative estimation of disease severity in both groups through evaluation of other 
prognostic features such as admission weight, HIV status, CD4 count, previous treatment 
history, resistance to 5 or more drugs, and mycobacterial load, which are all proxies of disease 
severity. Selection bias could have also impacted our findings including the cases and controls 
study design. However, all the patients were prospectively recruited in the same region and 
over a similar timeframe. It is possible that some patients with events could have been missed 
as the programme in the Western Cape became more decentralised. However, our recruitment 
network spanned the entire region and also utilised a region-wide electronic capture and 
surveillance system. 
In summary, our findings suggest that a bedaquiline-delamanid combination has a comparable 
long-term safety profile to a bedaquiline-based regimen in patients with drug-resistant TB 
irrespective of HIV status. Delamanid appeared to be a useful adjunct in the treatment of 
patients with poor prognostic features or high-level resistance where constituting an 
appropriate regimen would be otherwise challenging. These data inform regimen selection in 
patients with drug-resistant TB from TB endemic settings. 
  
Table 1: Comparison of demographic and clinical characteristics between patients in the 
bedaquiline and the combination regimen groups. Data are reflected as number of persons 
(%) or median (interquartile range) unless otherwise stated. 
Variables Patients who received 
bedaquiline-based 
regimen (n=82) 






Age (years) 33 (IQR 28-42) 34 (IQR 27-42) 0.04 
Gender (male) 50 (61.0) 24 (60.0) 0.92 
Weight at admission (kg) 51.8 (IQR 45.6- 58.3) 51.8 (IQR 43.3- 60.8) 0.36 
Days hospitalized 155 (IQR 93-210) 204 (IQR 124- 295) 0.38 
Number of medications 8 (IQR 7-9) 10 (IQR 8-11) 0.001 
5 likely effective medications 59 (72%) 26 (65%) 0.43 
Number of adverse events 2 (IQR 1-4) 3 (IQR 2-4) 0.51 
Time to culture positivity 
(days) 
14 (IQR 10-17) 10 (IQR 8-14) 0.46 
Diagnosis:  XDR-TB 67 (81.7) 19 (47.5) <0.001 
                   PRE-XDR TB 10 (12.2) 15 (37.5) <0.001 
                   MDR-TB 5 (6.1) 6 (15) <0.001 
 
Markers of disease severity 
Patients with weight <50kg 34 (41.5) 19 (47.5) 0.53 
Patients with previous MDR-
TB treatment failure 
10 (12.2) 21 (52.5) <0.001 
Patients with previous TB 
treatment 
40 (48.8) 29 (72.5) 0.01 
HIV-infected 42 (51.2) 22 (55.0) 0.69 
CD4 Count (cells/µl) 135 (60-279) 234 (52- 367) 0.41 
Patients with CD4<200 
cells/µl 
26 (31.7) 10 (29.4) 0.19 
Diabetic patient 2 (2.4) 1 (2.5) 0.98 
Patients resistant to ≥5 drugs 3 (3.7) 9 (22.5) 0.001 
Patients with either resistant 
to ≥ 5 drugs or previous 
treatment failure 
13 (15.9)  23(57.5) <0.001 
Smear grade>2 plusses  14 (17.1) 8 (20.0) 0.69 
Time to culture positivity≤ 7 
days 
9 (10.9) 7 (17.5) 0.32 
Treatment outcome 
Favourable outcome 52 (63.4) 27 (67.5) 0.66 
Unfavourable Outcome 30 (36.6) 13 (32.5)  
 
 
Table 2. List of drugs used in the bedaquiline-based regimen and bedaquiline-delamanid 
combination regimen and the proportion of patients who received them. Data is n (%). 
Drugs  Patients who received 
bedaquiline-based 
regimen (n=82) 





Kanamycin 16 (19.5) 8 (20) 0.95 
Terizidone 75 (91.5) 33 (82.5) 0.15 
Pyrazinamde 80 (97.6) 37 (92.5) 0.19 
Para-aminosalicylic acid 75 (91.5) 31 (77.5) 0.03 
Meropenem 0 (0) 5 (12.5) N/A* 
Any fluoroquinilone 81 (98.8) 37 (92.5) 0.07 
Moxifloxacin 26 (31.7) 16 (40) 0.37 
Levofloxacin 81 (98.8) 33 (82.5) 0.001 
Linezolid 67 (81.7) 36 (90) 0.24 
High dose Isoniazid 34 (41.5) 20 (50) 0.37 
Ethionamide 27 (32.9) 13 (32.5) 0.96 
Ethambutol 38 (46.3) 14 (35) 0.23 
Clofazimine 78 (95.1) 35 (87.5) 0.13 
Capreomycin 7 (8.5) 3 (7.5) 0.85 
Bedaquiline 82 (100) 40 (100) N/A* 
Delamanid 0 (0) 40 (100) N/A* 
N/A*: Not applicable 
 
 
                     
    Number at risk                                                                                                                    Number at risk 
 
    
    
Figure 1: Kaplan Meier estimate for the probability of achieving an unfavourable outcome (I) and the proportion of patients with culture positivity 
by the fifteenth month (II) in patients who received bedaquiline-based regimen (B) versus a bedaquiline-delamanid combination regimen (DB).                                                                   
B 52 46 42 41 40 40 
DB 26 25 24 21 16 16 
B 82 14 12 11 4 
DB 40 9 6 5 0 
  I 
II 
Table 3: Univariate and multivariate Cox proportional hazard model for developing 
unfavourable outcome in the whole cohort (N=122) 
Variables Hazard ratio (95% C.I) p-value 
Univariate analysis   
Age (years) 0.997 (0.967- 1.028) 0.85 
Gender (male) 1.231 (0.662-2.289) 0.51 
Weight (kg) 0.986 (0.960- 1.014) 0.33 
Age at admission < 50 years 1.137 (0.624- 2.070) 0.68 
HIV-infection 1.181 (0.874- 1.595) 0.28 
CD4 Count (cells/µl) 1.000 (0.998- 1.002) 0.84 
Previous TB treatment 1.013 (0.556- 1.848) 0.97 
Previous treatment failures 1.367 (0.580- 3.223) 0.48 
Days of admission 1.000 (0.997- 1.002) 0.87 
Clofazimine treatment 0.505 (0.122- 2.090) 0.35 
Delamanid treatment 0.877 (0.627- 1.225) 0.44 
Moxifloxacin treatment 1.023 (0.743- 1.408) 0.89 
Levofloxacin treatment 0.968 (0.473- 1.980) 0.93 
Any fluoroquinolone 0.897 (0.123- 6.555) 0.92 
Linezolid treatment 0.959 (0.426- 2.157) 0.92 
Bedaquiline-delamanid treatment 0.814 (0.416- 1.593) 0.55 
Number of medications 1.112 (0.935- 1.322) 0.23 
Number of adverse events 1.026 (0.898- 1.171) 0.71 
5 likely effective drugs 0.840 (0.589- 1.196) 0.33 
Resistant to >5 drugs 2.173 (0.900- 5.246) 0.08 
TTP* < 7 days 2.712 (1.331- 5.522) 0.006 
Smear grade  1.583 (0.779- 3.216) 0.20 
Multivariate Analysis 
HIV-infection 1.940 (0.791- 2.751) 0.22 
Isolate resistant to >5 drugs 1.940 (0.787- 4.779) 0.15 
TTP* < 7 days 2.681 (1.196- 6.011) 0.02* 
Number of medications 1.144 (0.957- 1.368) 0.14 
Smear grade 1.084 (0.489-2.403) 0.84 
Variables with p-value less than 0.3 were included in the multivariate model; TTP= time to 
culture positivity. 
Table 4: Adverse events reported by patients who received bedaquiline-based regimen and 
those who received bedaquiline-delamanid combination regimen. Data is n (%). 








Dizziness/disorientation 12 (14.6) 9 (22.5) 0.28 
Psychosis 3 (3.7) 6 (15) 0.02* 
Blurred vision 5 (6.1) 3 (7.5) 0.77 
Hearing loss 41 (50.0) 18 (45.0) 0.60 
Hypothyroidism 6 (7.3) 3 (7.5) 0.97 
Peripheral neuropathy 18 (22.0) 12 (30.0) 0.33 
Anaemia 28 (34.1) 15 (37.5) 0.72 
Diarrhoea 7 (8.5) 6 (15) 0.28 
Abdominal pain 16 (19.5) 5 (12.5) 0.34 
Vomiting 20 (24.4) 8 (20.0) 0.59 
Nausea 16 (19.5) 5 (12.5) 0.34 
Elevated liver enzyme  23 (28.0) 13 (32.5) 0.61 
Deranged renal 
function 
17 (20.7) 9 (22.5) 0.82 
Arthralgia 15 (18.3) 5 (12.5) 0.42 
*33.3% of patients who had psychosis in the bedaquiline-delamanid group received 
terizidone and high dose isoniazid in their regimen compared to 11% in the bedaquiline 
group; both drugs are associated with increased risk of developing psychosis. 
  
Table 5: QTcF profiles of patients who received bedaquiline-based regimen and those who 
received bedaquiline-delamanid combination regimen in the whole cohort and in HIV-
infected patients. Data is n (%) and median (interquartile range). 
Variable Patients who received 
bedaquiline-based regimen  
Patients who received 
bedaquiline-delamanid 
combination therapy  
p-values  
Whole cohort n=82 n=40  
Baseline QTcF 408 (IQR 388-425) 419 (IQR 389-436) 0.32 
Maximum QTcF change from 
baseline 
27 (IQR 13-42) 23 (IQR 8-54) 0.11 
Patients with QTcF increment 
from baseline greater than 60 ms 
6 (7.3) 7 (20.6) <0.001 
Patients with at least one QTcF 
greater than 450 ms 
16 (19.5) 15 (44.1) <0.001 
Patients with at least one QTcF 
greater than 500 ms 
0 (0) 0 (0) N/A* 
HIV-infected patients n=42 n=22 p-values 
Baseline QTcF 407 (IQR 385-428) 417 (IQR 378- 436) 0.54 
QTcF change from baseline 32 (IQR 14-44) 22 (IQR 6-56) 0.19 
Patients with QTcF difference 
greater than 60 ms 
5 (11.9) 4 (18.2) 0.49 
Patients with QTcF greater than 
450 ms 
11 (26.2) 7 (31.8) 0.32 
Patients with QTcF greater than 
500 ms 
0 (0) 0 (0) N/A* 
HIV uninfected patients 
 
n=40 n=18  
Baseline QTcF 409 (IQR 394- 419) 419 (IQR 393-429) 0.21 
QTcF change from baseline 22 (IQR 12- 37) 32 (IQR 13- 52) 0.48 
Patients with QTcF difference 
greater than 60 ms 
1 3 0.06 
Patients with QTcF greater than 
450 ms 
5 8 0.02 
Patients with QTcF greater than 
500 ms 
0 0 N/A* 
N/A*: Not applicable 
 
 
Table 6: Cox proportional hazard model for having at least one QTc value of greater than 
450ms 
Variables Hazard ratio (95% C.I) p-value 
Univariate analysis   
Age (years) 1.031 (0.998- 1.066) 0.07 
Gender (male) 1.221 (0.570- 2.614) 0.61 
Weight (kg) 0.980 (0.948- 1.014) 0.24 
Age at admission < 50 years 0.427 (0.146-1.248) 0.12 
HIV-infection 1.043 (0.504- 2.158) 0.91 
Previous TB treatment 1.195 (0.579- 2.466) 0.63 
Previous treatment failures 1.304 (0.536- 3.173) 0.56 
Days of admission 1.002 (1.000- 1.004) 0.06 
Clofazimine treatment 0.731 (0.220- 2.426) 0.61 
Delamanid treatment 3.668 (1.712- 7.859) 0.001 
Moxifloxacin treatment 1.306 (0.619- 2.757) 0.48 
Levofloxacin treatment 1.564 (0.748- 3.271) 0.24 
Linezolid treatment 0.605 (0.244-1.501) 0.28 
Number of medications 1.104 (0.884- 1.380) 0.38 
Number of adverse events 0.976 (0.832- 1.145) 0.77 
5 likely effective drugs 2.025 (0.761- 5.386) 0.16 
TTP* < 7 days 0.777 (0.184- 3.282) 0.73 




5 likely effective drugs 3.167 (0.995- 10.08) 0.05 
Age 1.039 (1.000- 1.078) 0.04 
Delamanid treatment 3.504 (1.544- 7.954) 0.003 
Linezolid treatment 0.539 (0.200- 1.454) 0.22 
Levofloxacin treatment 1.357 (0.494- 3.730) 0.55 
Days of admission 1.001 (0.998- 1.004) 0.46 




1. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018. 
Licence: CC BY-NC-SA 3.0 IGO. In. 
2. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, 
Nardell EA, London L, Lessem E et al: The epidemiology, pathogenesis, transmission, 
diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable 
tuberculosis. Lancet Respir Med 2017, 5(4):291-360. 
3. Dheda K, Barry CE, Maartens G: Tuberculosis. The Lancet 2016, 387(10024):1211-
1226. 
4.  WHO position statement on the use of delamanid for MDR-TB. Licence: CC BY-
NC-SA 3.0 IGO. In. 
5. WHO Consolidated Guidelines Drug-resistant tuberculosis treatment In. Geneva: 
World Health Organization; 2019. 
6. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTBt, 
Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry 
PM, Bastos ML et al: Treatment correlates of successful outcomes in pulmonary multidrug-
resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018, 392(10150):821-
834. 
7. Olayanju O, Limberis J, Esmail A, Oelofse S, Gina P, Pietersen E, Fadul M, Warren 
R, Dheda K: Long-term bedaquiline-related treatment outcomes in patients with extensively 
drug-resistant tuberculosis from South Africa. The European respiratory journal 2018, 51(5). 
8. Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, Hughes J, 
Ferreira H, Padanilam X, Romero R et al: Effect of bedaquiline on mortality in South African 
patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 
2018. 
9. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane 
V, Andries K, Bakare N, De Marez T et al: Multidrug-resistant tuberculosis and culture 
conversion with bedaquiline. N Engl J Med 2014, 371(8):723-732. 
10. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, 
Jin B et al: Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl 
J Med 2012, 367(16):1508-1518. 
11. Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, te 
Riele J, Mastrapa B, Streicher EM et al: Outcomes, infectiousness, and transmission 
dynamics of patients with extensively drug-resistant tuberculosis and home-discharged 
patients with programmatically incurable tuberculosis: a prospective cohort study. The Lancet 
Respiratory Medicine 2017, 5(4):269-281. 
12. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, 
Corander J, Bryant J, Parkhill J, Nejentsev S et al: Evolution and transmission of drug-
resistant tuberculosis in a Russian population. Nat Genet 2014, 46(3):279-286. 
13. Shah NS, Auld SC, Brust JC, Mathema B, Ismail N, Moodley P, Mlisana K, Allana S, 
Campbell A, Mthiyane T et al: Transmission of Extensively Drug-Resistant Tuberculosis in 
South Africa. N Engl J Med 2017, 376(3):243-253. 
14. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori G, 
Warren R: Global control of tuberculosis: from extensively drug-resistant to untreatable 
tuberculosis. The Lancet Respiratory Medicine 2014, 2(4):321-338. 
15. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, 
Nardell EA, London L, Lessem E et al: The epidemiology, pathogenesis, transmission, 
diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable 
tuberculosis. Lancet Respir Med 2017. 
16. Olayanju O, Esmail A, Limberis J, Gina P, Dheda K: Linezolid Interruption in 
Patients with Fluoroquinolone- Resistant Tuberculosis Receiving a Bedaquiline-Based 
Treatment Regimen. Int J Infect Dis 2019. 
17. von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Jr., Ticona E, Segura 
P, Cadena E, Yu C, Cirule A, Lizarbe V et al: Efficacy and safety of delamanid in 
combination with an optimised background regimen for treatment of multidrug-resistant 
tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group 
phase 3 trial. Lancet Respir Med 2019. 
18. Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, De Azevedo V, 
Kock Y, Steele SJ, Shroufi A et al: Delamanid for rifampicin-resistant tuberculosis: a 
retrospective study from South Africa. Eur Respir J 2018, 51(6). 
19. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule 
A, Leimane V, Kurve A, Levina K et al: Delamanid improves outcomes and reduces 
mortality in multidrug-resistant tuberculosis. Eur Respir J 2013, 41(6):1393-1400. 
20. Lewis JM, Sloan DJ: The role of delamanid in the treatment of drug-resistant 
tuberculosis. Ther Clin Risk Manag 2015, 11:779-791. 
21. Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB: Cardiac safety of 
bedaquiline: a systematic and critical analysis of the evidence. In.: Eur Respiratory Soc; 
2017. 
22. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim 
policy guidance. Geneva, World Health Organisation. 2014. In. 
23. Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, 
Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A et al: Early safety and efficacy of 
the combination of bedaquiline and delamanid for the treatment of patients with drug-
resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. The 
Lancet Infectious Diseases 2018, 18(5):536-544. 
24. Kim CT, Kim TO, Shin HJ, Ko YC, Hun Choe Y, Kim HR, Kwon YS: Bedaquiline 
and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort 
study in Korea. Eur Respir J 2018, 51(3). 
25. Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, 
Spanevello A, Migliori GB: Combined treatment of drug-resistant tuberculosis with 
bedaquiline and delamanid: a systematic review. Eur Respir J 2018, 52(1). 
26. World Health Organization. WHO Position Statement on the Use of Delamanid for 
the Treatment of Multidrug-Resistant Tuberculosis. In.; 2018. 
27. Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, Badri M, 
Lesosky M, van Helden P, Sirgel FA et al: Long-term outcomes of patients with extensively 
drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014. 
28. Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, Te 
Riele J, Mastrapa B, Streicher EM et al: Outcomes, infectiousness, and transmission 
dynamics of patients with extensively drug-resistant tuberculosis and home-discharged 
patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet 
Respir Med 2017, 5(4):269-281. 
29. Dheda K, Migliori GB: The global rise of extensively drug-resistant tuberculosis: is 






A regimen containing bedaquiline and delamanid compared to bedaquiline alone in 
patients with drug resistant tuberculosis with poor prognosis 
 Olatunde Olayanju1, *, Aliasgar Esmail1, *, Jason Limberis1, Keertan Dheda1,2 
Affiliations: 1Centre for Lung Infection and Immunity Unit, Division of Pulmonology, 
Department of Medicine, University of Cape Town, South Africa. 
2. Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, 
London School of Hygiene and Tropical Medicine, London, UK 
*Co-first author 
Correspondence: Keertan Dheda, Centre for Lung Infection and Immunity Unit, Division of 
Pulmonology, Department of Medicine University of Cape Town.H46.41 Old Main 




Table S1: Culture conversion status of patients who received bedaquiline-based and those 
who received bedaquiline-delamanid combination regimens at different time points during 
treatment. Data is n (%). 
 Patients who received 
bedaquiline-based 
regimen (n=82) 





Positive at baseline  52/82 (63.4) 26/40 (65.0) 0.86 
Culture Conversion 
at 2 months 
25/38 (65.8) 13/23 (56.5) 0.47 
Culture Conversion 
at 6 months 
33/36 (92.5) 18/22 (81.8) 0.26   
Culture Conversion 
at 12 months 
27/31 (87.1) 13/15 (86.7) 0.97 
Patients who were culture negative at the point of recruitment were excluded from the 
analysis at 2, 6 and 12 months. 
  
 
Table S2: Comparison of treatment outcomes between patients who received bedaquiline-
based regimen and those who received delamanid-bedaquiline combination regimen. Data is 
(n)% 
 Patients who received 
bedaquiline-based 
regimen (n=82) 





XDR-TB  n=67 n=19  
Favourable outcome 44 (65.7) 14 (73.7) 0.51 
Unfavourable Outcome  23 (34.3) 5 (26.3) 
PRE-XDRTB  n=10 n=15  
Favourable outcome 4 (40) 9 (60) 0.32 
Unfavourable Outcome 6 (60) 6 (40) 
MDR-TB  n=5 n=6  
Favourable outcome 4 (80) 4 (66.67) 0.62 





Figure S1: QTcF values at different time points during treatment with either bedaquiline-
based regimen or delamanid-bedaquiline combination regimen. Boxes represent the median 
and IQR, while error bars represent range values 
  
 
Table S3: (A) Univariate Cox proportional hazard model for developing unfavourable 
outcome in the HIV-infected patients 
Variables Hazard ratio (95% C.I) p-value 
Age (years) 1.013 (0.960- 1.068) 0.64 
Gender (male) 1.173 (0.479- 2.871) 0.73 
Weight (kg) 0,981 (0.945- 1.018) 0.31 
Age at admission < 50 years 0.206 (0.058- 0.734) 0.02 
Previous TB treatment 1.808 (0.748- 4.367) 0.19 
Days of admission 0.993 (0.986- 0.999) 0.03 
Clofazimine treatment 0.596 (0.080- 4.467) 0.62 
Delamanid treatment 0.785 (0.485- 1.269) 0.32 
Moxifloxacin treatment 1.262 (0.484- 3.293) 0.64 
Levofloxacin treatment 0.883 (0.116- 6.717) 0.88 
Any fluoroquinolone 0.047 (0.000-10560) 0.63 
Linezolid treatment 0.416 (0.056- 3.109) 0.39 
Delamanid-bedaquiline treatment 0.651 (0.248- 1.706) 0.38 
Number of medications 1.099 (0.847- 1.426) 0.48 
Number of adverse events 1.137 (0.960-1.347) 0.14 
5 likely effective drugs 0.684 (0.395- 1.183) 0.17 
Resistant to >5 drugs 2.688 (0.762- 9.482) 0.12 
TTP* < 7 days 1.709 (0.570- 5.119) 0.34 
SMG# > 2 plusses 2.270 (0.752- 6.847) 0.15 
(B) Multivariate Cox proportional hazard model for unfavourable outcome  
Age at admission < 50 years 0.333 (0.079-1.396) 0.13 
Resistant to >5 drugs 4.725 (1.041-21.43) 0.04 
Previous TB treatment 2.181 (0.810- 5.871) 0.12 
Days of admission 0.990 (0.982- 0.998) 0.02 
5 likely effective drugs 0.465 (0.142- 1.520) 0.21 
Number of adverse events 1.173 (0.949- 1.449) 0.14 
SMG# > 2 plusses 2.442 (0.690- 8.640) 0.17 
 
 
Table S4: Adverse events reported by HIV-infected patients who received bedaquiline-based 
regimen and those who received delamanid-bedaquiline combination regimen. Data is n (%). 








Dizziness/disorientation 5 (11.9) 4 (18.2) 0.49 
Psychosis 2 (4.8) 4 (18.2) 0.08 
Blurred vision 1 (2.4) 2 (9.1) 0.23 
Hearing loss 20 (47.6) 8 (36.4) 0.39 
Hypothyroidism 4 (9.5) 2 (9.1) 0.96 
Peripheral neuropathy 6 (14.3) 7 (31.8) 0.098 
Anaemia 7 (16.7) 11 (50) 0.005* 
Diarrhoea 3 (7.1) 4 (18.2) 0.18 
Abdominal pain 8 (19.0) 1 (4.5) 0.11 
Vomiting 11 (26.2) 4 (18.2) 0.47 
Nausea 9 (21.4) 3 (13.6) 0.45 
Elevated liver enzyme 15 (35.7) 8 (36.4) 0.96 
Deranged renal 
function 
12 (28.6) 8 (36.4) 0.52 
Arthralgia 8 (19) 3 (13.6) 0.59 
*95.5% of patients in the bedaquiline-delamanid group received linezolid in their regimen 







Figure S2 (A): Kaplan Meier estimate for the probability of culture conversion and (B) the 
probability of achieving an unfavourable outcome in HIV-infected patients who received 
bedaquiline-alone regimen and those who received delamanid-bedaquiline combination 
regimen. 
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